Andres Matoso

Andres Matoso

Auto-generated profile, based on publicly available information

Andres Matoso

Johns Hopkins School of Medicine

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2018 in Histopathology
Verified
Journal Article
Closed access
PDF file
AMAndres Matoso
Andres Matoso
JEJonathan I Epstein
Jonathan I Epstein

23 April 2021 in Applied Immunohistochemistry & Molecular Morphology
Verified
Journal Article
Closed access
JHJean H. Hoffman-Censits
Jean H. Hoffman-Censits
KLKara A. Bs Lombardo
Kara A. Bs Lombardo
VPVamsi Parimi
Vamsi Parimi
SKSonia Kamanda
Sonia Kamanda
WCWoonyoung Choi
Woonyoung Choi
AMAndres Matoso
Andres Matoso
The antibody-drug conjugate enfortumab-vedotin acts by targeting nectin-4, a protein that is nearly ubiquitously expressed in conventional urothelial cancer. However, expression of nectin-4 in morphologic variants of urothelial carcinoma and nonurothelial histotypes was unknown. Immunohistochemistry for nectin-4 using was performed on 169 patients including 83 with nonmuscle invasive bladder cancer and 86 patients with muscle invasive bladder cancer. Staining was scored for intensity (0 to 3) and extent (% positive cells) using the histological score system, where >15 was considered positive. Overall, 72/83 (87%) samples of nonmuscle invasive urothelial carcinoma were positive, including 29/30 (97%) noninvasive papillary urothelial carcinomas, 7/8 (87.5%) carcinomas in situ, 36/45 (80%) papillary urothelial carcinomas invading the lamina propria. Overall, 50/86 muscle invasive tumors were positive, including 15/22 (68.2%) urothelial carcinomas, 7/10 (70%) squamous cell carcinomas, 3/11 (28%) micropapillary tumors, 4/6 (66%) adenocarcinomas, 2/4 (50%) nested carcinomas, 5/8 (63%) plasmacytoid, 1/10 (10%) sarcomatoid carcinomas, and 0/15 (0%) small cell carcinomas. Whole transcriptome RNA sequencing revealed that compared with conventional urothelial carcinomas, most sarcomatoid carcinomas and all but 2 small cell carcinomas expressed very low levels of nectin-4 mRNA but expressed significant levels of either trop2 or ERBB2, which are the molecular targets of 2 other antibody-drug conjugates—sacituzumab gavitecan (trop2) or trastuzumab deruxtecan (ERBB2/HER2). In summary, our study demonstrates that there is heterogeneity of expression of nectin-4 in morphologic variants of urothelial cancer and nonurothelial histotypes, and suggests that testing expression of nectin-4 should be considered in morphologic variants or nonurothelial histotypes found to have lower expression.

12 September 2017 in Histopathology
Verified
Journal Article
Closed access
PDF file
YLYunjie Li
Yunjie Li
VRVictor E Reuter
Victor E Reuter
AMAndres Matoso
Andres Matoso
GNGeorge J Netto
George J Netto
JEJonathan I Epstein
Jonathan I Epstein
PAPedram Argani
Pedram Argani

1 June 2018 in Human Pathology
Verified
Journal Article
Closed access
AMAndres Matoso
Andres Matoso
BKBinny Khandakar
Binny Khandakar
SYSongyang Yuan
Songyang Yuan
TWTony Wu
Tony Wu
LWLi J. Wang
Li J. Wang
EYEvgeny Yakirevich
Evgeny Yakirevich

1 September 2018 in Neoplasia
Verified
Journal Article
Open access
BCBalabhadrapatruni V.S.K. Chakravarthi
Balabhadrapatruni V.S.K. Chakravarthi
MPMaria Del Carmen Rodriguez Pena
Maria Del Carmen Rodriguez Pena
SASumit Agarwal
Sumit Agarwal
DCDarshan S. Chandrashekar
Darshan S. Chandrashekar
SBSai Akshaya Hodigere Balasubramanya
Sai Akshaya Hodigere Balasubramanya
Sooryanarayana VaramballySooryanarayana Varambally
Sooryanarayana Varambally
Genomic and transcriptome sequencing of bladder cancer (BLCA) has identified multiple molecular alterations during cancer progression. Many of these identified genetic and epigenetic changes play a role in the progression of this disease. Studies have identified molecular subtypes in muscle-invasive bladder cancer (MIBC) with different sensitivities to frontline therapy suggesting the heterogeneity in these tumors and the importance of molecular characterization of MIBC to provide effective treatment. Specifically, it has become increasingly evident, as demonstrated by The Cancer Genome Atlas project, that metabolic enzymes are commonly dysregulated in BLCA. Elevated expression of multiple metabolic enzymes is due to the increased demand from rapidly proliferating BLCA cells requiring extensive nucleotide synthesis. Cancer cells utilize the de novo purine and pyrimidine biosynthetic pathway as a source of their nucleotide needs. In this study, we show that phosphoribosyl aminoimidazole succinocarboxamide synthetase (PAICS), an enzyme involved in de novo purine biosynthetic pathway, is significantly overexpressed in BLCA. Immunohistochemical staining of paraffin-embedded tissue sections showed that PAICS is overexpressed in MIBC. Furthermore, we found that tumor suppressor miR-128 negatively regulated PAICS expression by binding to its 3'-untranslated region. We also found that PAICS induces EMT by positively regulating SNAI1 and by a reduction in E-cadherin expression. Additionally, our in vitro functional studies and in vivo chicken chorioallantoic membrane assay show that PAICS plays a critical role in BLCA cell proliferation, invasion, and tumor growth. Collectively, our data suggest that targeting PAICS may provide a therapeutic option in BLCA.

21 November 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PSPritam Sadhukhan
Pritam Sadhukhan
MFMingxiao Feng
Mingxiao Feng
EIEmily J. Illingworth
Emily J. Illingworth
ISIdo Sloma
Ido Sloma
AOAkira Ooki
Akira Ooki
Mohammad Obaidul HoqueMohammad Obaidul Hoque
Mohammad Obaidul Hoque
The Hippo signaling pathway plays a key role in tumorigenesis in different cancer types. We investigated the role of the Hippo “effector” YAP1 on the tumor immune microenvironment (TIME) of urothelial carcinoma of bladder (UCB) and evaluated the efficacy of immunotherapy in the context of YAP1 signaling. We performed numerous in vitro and in vivo experiments to determine the role of YAP1 using genetic and pharmacological attenuation of YAP1 activity. Briefly, RNA sequencing was carried out with mice and human cell lines to identify novel YAP1-regulated downstream targets unbiasedly. We then experimentally confirmed that YAP1 regulates the TIME through the IL-6/STAT3 signaling pathway and varied C-X-C motif chemokine regulation. We analyzed several human sample sets to explore the TIME status in the context of YAP1 expression. Our data indicate that YAP1 attenuation decreases M2 macrophages and MDSCs in the TIME compared to YAP1 expressing cells. In summary, this study provides insights on YAP1 signaling as a driver for cancer stemness and an inducer of immunosuppressive TIME. Moreover, the therapeutic efficacy of YAP1 attenuation indicates that combined blockade of YAP1 and immune checkpoints may yield clinical value for treating UCB patients.